Florida adult chat trials
So far, the trial has exceeded this goal, with about 60% of the enrolled patients having cancers other than colon, rectal, breast, non-small cell lung, or prostate.
If patients enroll in a treatment arm, the trial covers the drug used in that arm.The primary goal for MATCH is to determine the percentage of patients whose tumors have a complete or partial response to treatment, meaning the tumors shrink by a certain amount. Treatments will be considered promising if at least 16% of the patients in an arm have tumor shrinkage.This threshold was chosen to reduce the chance that a treatment that is not working will appear promising while also improving the chance that a treatment that is working will appear promising.Genomic sequencing is a laboratory method that is used to determine the genetic makeup of cancer cells.Patients whose tumors have genetic changes that match one of the treatments in the trial may receive that treatment, if they meet other eligibility criteria.NCI-MATCH, also known as MATCH, is a precision medicine cancer treatment clinical trial.
In this trial, patients are assigned to receive treatment based on the genetic changes found in their tumors through genomic sequencing and other tests.
As the trial progresses, new clinical sites will be added.
Patients, families, and clinicians can also contact NCI’s Cancer Information Service to learn more about the COMET study.
NCI-MATCH is supported by NCI and is coordinated by the ECOG-ACRIN Cancer Research Group.
Personnel from NCI, ECOG-ACRIN, and the other adult trial groups in the NCI-supported National Clinical Trials Network (NCTN)—the Alliance for Clinical Trials in Oncology, NRG Oncology Group, and SWOG—have collaborated in the development of NCI-MATCH.
The trial seeks to determine whether treating cancer based on these specific genetic changes is effective.